Company Overview
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the treatment of highly resistant cancers. We have three core technologies, all of which are based on discoveries made by Dr. Waldemar Priebe and his team at The University of Texas MD Anderson Cancer Center. Our clinical stage drugs are Annamycin, a Next Generation Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, or AML, and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional Immune/Transcription Modulators, as well as Metabolism/Glycosylation Inhibitors.

Our Next Generation Anthracycline, Annamycin, is unlike any currently approved anthracyclines, as it is designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin has preliminary clinical data suggesting its potential to become the first successful therapy suitable for the majority of relapsed or refractory AML patients and is currently in two Phase I/II clinical trials.

WP1066 is one of several Immune/Transcription Modulators capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1α. These transcription factors are widely sought targets that may also play a role in the inability of immune checkpoint inhibitors to affect more resistant tumors.

We are also developing new prodrugs to exploit the potential uses of inhibitors of glycolysis. Our lead Metabolism/Glycosylation Inhibitor compound, WP1122, provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells. New research also points to the potential for the glucose decoy (2-DG) within WP1122 to be capable of enhancing the usefulness of checkpoint inhibitors.

Management Team
Walter V. Klemp
Founder, President, Chairman, CEO, and Business Advisory Board Member

Donald Picker, PhD
Chief Scientific Officer

Robert Shepard, MD, FACP
Chief Medical Officer - Hematology

Sandra Silberman, MD, PhD
Chief Medical Officer - New Products

Jonathan P. Foster
Chief Financial Officer

Moleculin Biotech, Inc.
5300 Memorial Drive
Suite 950
Houston, TX 77007

Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme
Dec 1 2021, 8:35 AM EST

Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event
Nov 12 2021, 8:05 AM EST

Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update
Nov 11 2021, 8:05 AM EST

Stock Overview
Symbol: MBRX
Exchange: Nasdaq
Market Cap: $ - $ 52-Week

Investor Relations
JTC Team, LLC.
Jenene Thomas
T: 833-475-8247
mbrx@jtcir.com
Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.